- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05904080
Test af Nivolumab og Ipilimumab immunterapi med eller uden det målrettede lægemiddel Cabozantinib ved tilbagevendende, metastatisk eller uhelbredelig nasopharyngeal cancer
Randomiseret fase 2-undersøgelse af nivolumab og ipilimumab med eller uden cabozantinib hos patienter med avanceret nasopharyngeal karcinom, der er udviklet efter platinbehandling og immunterapi
This phase II trial tests how well nivolumab and ipilimumab immunotherapy with or without cabozantinib works in treating patients with nasopharyngeal cancer that has come back (after a period of improvement) (recurrent), has spread from where it first started (primary site) to other places in the body (metastatic), or for which no treatment is currently available (incurable). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Giving immunotherapy with nivolumab and ipilimumab and targeted therapy with cabozantinib may help shrink and stabilize nasopharyngeal cancer.
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
PRIMARY OBJECTIVE:
I. To determine if the progression-free survival (PFS) of the triplet combination (cabozantinib S-malate, nivolumab, and ipilimumab [CaboNivoIpi]) is more favorable than the doublet (nivolumab and ipilimumab [NivoIpi]).
SECONDARY OBJECTIVES:
I. To compare safety and tolerability between the two arms (Common Terminology Criteria for Adverse Events [CTCAE] version [v]5.0.).
II. To compare overall response rate (ORR) between the two arms via both Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune-modified Response Evaluation Criteria in Solid Tumors (iRECIST) criteria.
III. To compare overall survival (OS) between the two arms. IV. To assess response by primary or acquired PD-1/L1 inhibitor resistance in the prior line of therapy.
EXPLORATORY OBJECTIVE:
I. To evaluate molecular and immunologic predictors of response (Epstein-Barr virus [EBV] viral load; PD-L1 score) between arms.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive nivolumab intravenously (IV) over 30 minutes and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) or magnetic resonance imaging (MRI) and collection of blood samples throughout the trial.
ARM B: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1 and cabozantinib S-malate orally (PO) daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients may continue with cabozantinib S-malate after 2 years per treating investigator. Patients undergo CT or MRI and collection of blood samples throughout the trial.
After completion of study treatment, patients are followed up every 8-12 weeks until progression of disease occurs or a new non-protocol anti-cancer therapy is initiated and then every 6 months for up to 2 years.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
California
-
Irvine, California, Forenede Stater, 92612
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
-
Los Angeles, California, Forenede Stater, 90033
- USC / Norris Comprehensive Cancer Center
-
Los Angeles, California, Forenede Stater, 90020
- Keck Medicine of USC Koreatown
-
Los Angeles, California, Forenede Stater, 90033
- Los Angeles General Medical Center
-
Newport Beach, California, Forenede Stater, 92663
- USC Norris Oncology/Hematology-Newport Beach
-
Orange, California, Forenede Stater, 92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Palo Alto, California, Forenede Stater, 94304
- Stanford Cancer Institute Palo Alto
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30308
- Emory University Hospital Midtown
-
-
Idaho
-
Boise, Idaho, Forenede Stater, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Caldwell, Idaho, Forenede Stater, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene, Idaho, Forenede Stater, 83814
- Kootenai Health - Coeur d'Alene
-
Nampa, Idaho, Forenede Stater, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Post Falls, Idaho, Forenede Stater, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Forenede Stater, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60611
- Northwestern University
-
Chicago, Illinois, Forenede Stater, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Forenede Stater, 60612
- University of Illinois
-
Danville, Illinois, Forenede Stater, 61832
- Carle at The Riverfront
-
DeKalb, Illinois, Forenede Stater, 60115
- Northwestern Medicine Cancer Center Kishwaukee
-
Effingham, Illinois, Forenede Stater, 62401
- Carle Physician Group-Effingham
-
Evanston, Illinois, Forenede Stater, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Geneva, Illinois, Forenede Stater, 60134
- Northwestern Medicine Cancer Center Delnor
-
Glenview, Illinois, Forenede Stater, 60026
- NorthShore University HealthSystem-Glenbrook Hospital
-
Glenview, Illinois, Forenede Stater, 60026
- Northwestern Medicine Glenview Outpatient Center
-
Grayslake, Illinois, Forenede Stater, 60030
- Northwestern Medicine Grayslake Outpatient Center
-
Harvey, Illinois, Forenede Stater, 60426
- Ingalls Memorial Hospital
-
Highland Park, Illinois, Forenede Stater, 60035
- NorthShore University HealthSystem-Highland Park Hospital
-
Lake Forest, Illinois, Forenede Stater, 60045
- Northwestern Medicine Lake Forest Hospital
-
Mattoon, Illinois, Forenede Stater, 61938
- Carle Physician Group-Mattoon/Charleston
-
New Lenox, Illinois, Forenede Stater, 60451
- UC Comprehensive Cancer Center at Silver Cross
-
Orland Park, Illinois, Forenede Stater, 60462
- University of Chicago Medicine-Orland Park
-
Orland Park, Illinois, Forenede Stater, 60462
- Northwestern Medicine Orland Park
-
Urbana, Illinois, Forenede Stater, 61801
- Carle Cancer Center
-
Warrenville, Illinois, Forenede Stater, 60555
- Northwestern Medicine Cancer Center Warrenville
-
-
Iowa
-
Ankeny, Iowa, Forenede Stater, 50023
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Clive, Iowa, Forenede Stater, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Forenede Stater, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Council Bluffs, Iowa, Forenede Stater, 51503
- Heartland Oncology and Hematology LLP
-
Council Bluffs, Iowa, Forenede Stater, 51503
- Methodist Jennie Edmundson Hospital
-
Council Bluffs, Iowa, Forenede Stater, 51503
- Nebraska Cancer Specialists/Oncology Hematology West PC - MEJ
-
Des Moines, Iowa, Forenede Stater, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Forenede Stater, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Forenede Stater, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Forenede Stater, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Waukee, Iowa, Forenede Stater, 50263
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02111
- Tufts Medical Center
-
-
Minnesota
-
Bemidji, Minnesota, Forenede Stater, 56601
- Sanford Joe Lueken Cancer Center
-
-
Missouri
-
St Louis, Missouri, Forenede Stater, 63128
- Mercy Hospital South
-
-
Montana
-
Anaconda, Montana, Forenede Stater, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Forenede Stater, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, Forenede Stater, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, Forenede Stater, 59405
- Benefis Sletten Cancer Institute
-
Kalispell, Montana, Forenede Stater, 59901
- Logan Health Medical Center
-
Missoula, Montana, Forenede Stater, 59804
- Community Medical Center
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68114
- Nebraska Methodist Hospital
-
Omaha, Nebraska, Forenede Stater, 68114
- Oncology Associates PC
-
Omaha, Nebraska, Forenede Stater, 68114
- Nebraska Cancer Specialists/Oncology Hematology West PC - MECC
-
-
New Jersey
-
Basking Ridge, New Jersey, Forenede Stater, 07920
- Memorial Sloan Kettering Basking Ridge
-
Middletown, New Jersey, Forenede Stater, 07748
- Memorial Sloan Kettering Monmouth
-
Montvale, New Jersey, Forenede Stater, 07645
- Memorial Sloan Kettering Bergen
-
-
New York
-
Commack, New York, Forenede Stater, 11725
- Memorial Sloan Kettering Commack
-
Harrison, New York, Forenede Stater, 10604
- Memorial Sloan Kettering Westchester
-
New York, New York, Forenede Stater, 10065
- Memorial Sloan Kettering Cancer Center
-
Uniondale, New York, Forenede Stater, 11553
- Memorial Sloan Kettering Nassau
-
-
North Carolina
-
Chapel Hill, North Carolina, Forenede Stater, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Charlotte, North Carolina, Forenede Stater, 28204
- Novant Health Presbyterian Medical Center
-
Huntersville, North Carolina, Forenede Stater, 28078
- Novant Health Cancer Institute - Huntersville
-
Matthews, North Carolina, Forenede Stater, 28105
- Novant Health Cancer Institute - Matthews
-
Mooresville, North Carolina, Forenede Stater, 28117
- Novant Health Cancer Institute - Mooresville
-
-
North Dakota
-
Bismarck, North Dakota, Forenede Stater, 58501
- Sanford Bismarck Medical Center
-
Fargo, North Dakota, Forenede Stater, 58122
- Sanford Roger Maris Cancer Center
-
Fargo, North Dakota, Forenede Stater, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 45220
- Good Samaritan Hospital - Cincinnati
-
-
Oklahoma
-
Lawton, Oklahoma, Forenede Stater, 73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City, Oklahoma, Forenede Stater, 73104
- University of Oklahoma Health Sciences Center
-
Tulsa, Oklahoma, Forenede Stater, 74146
- Oklahoma Cancer Specialists and Research Institute-Tulsa
-
-
Oregon
-
Ontario, Oregon, Forenede Stater, 97914
- Saint Alphonsus Cancer Care Center-Ontario
-
Portland, Oregon, Forenede Stater, 97239
- Oregon Health and Science University
-
-
South Carolina
-
Charleston, South Carolina, Forenede Stater, 29425
- Medical University of South Carolina
-
-
South Dakota
-
Sioux Falls, South Dakota, Forenede Stater, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls, South Dakota, Forenede Stater, 57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37232
- Vanderbilt University/Ingram Cancer Center
-
-
Virginia
-
Richmond, Virginia, Forenede Stater, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Forenede Stater, 23298
- VCU Massey Comprehensive Cancer Center
-
-
West Virginia
-
Morgantown, West Virginia, Forenede Stater, 26506
- West Virginia University Healthcare
-
Parkersburg, West Virginia, Forenede Stater, 26101
- Camden Clark Medical Center
-
-
Wisconsin
-
Eau Claire, Wisconsin, Forenede Stater, 54701
- Marshfield Medical Center-EC Cancer Center
-
Marshfield, Wisconsin, Forenede Stater, 54449
- Marshfield Medical Center-Marshfield
-
Minocqua, Wisconsin, Forenede Stater, 54548
- Marshfield Medical Center - Minocqua
-
Rice Lake, Wisconsin, Forenede Stater, 54868
- Marshfield Medical Center-Rice Lake
-
Stevens Point, Wisconsin, Forenede Stater, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Weston, Wisconsin, Forenede Stater, 54476
- Marshfield Medical Center - Weston
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Patients must have histologically documented nasopharyngeal carcinoma (NPC) regardless of World Health Organization (WHO) classification (keratinizing squamous cell carcinoma, non-keratinizing, or basaloid squamous cell carcinoma) and regardless of association with Epstein-Barr virus (EBV) and/or human papillomavirus (HPV)
-
Recurrent, metastatic and incurable disease treated with platinum-gemcitabine and prior PD-1/L1 blockade (as first or second-line therapy)
-
Patients are eligible regardless of prior smoking history, p16 immunohistochemistry (IHC) status, PD-L1 expression status, EBV tumor status, EBV viral load at baseline, or tumor genomic alteration status
-
Patients must have at least one measurable lesion (by RECIST v1.1) which has not been previously irradiated that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions as >= 10 mm (>= 1 cm) (and short axis for nodal lesions, LN >= 15 mm) with CT scan, MRI, or calipers by clinical exam
-
Patients may have had no more than 2 prior lines of prior systemic therapy for recurrent, metastatic NPC
-
No prior VEGFR targeted therapy permitted
-
Age >= 18 years
-
Eastern Cooperative Oncology Group Performance (ECOG) performance status 0-2
-
Absolute neutrophil count (ANC) >= 1,000/mm^3
-
Hemoglobin >= 9 g/dL
-
Platelet count >= 100,000/mm^3
-
Creatinine or creatinine clearance =< 1.5 mg/dL or >= 30 Modification of Diet in Renal Disease (MDRD)
-
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN); except subjects with Gilbert syndrome who can have a total bilirubin < 3 mg/dL
-
Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGT]) =< 3 x upper limit of normal (ULN)
- Up to =< 5 allowed with liver metastases
-
Not pregnant and not nursing, because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown. Therefore, for women of childbearing potential only, a negative urine or serum pregnancy test, per institution standard, done =< 7 days prior to registration is required.
- Pregnant women are excluded from this study because nivolumab, ipilimumab, and cabozantinib are all Class C or D agents with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants, secondary to treatment of the mother with any of the study agents, breastfeeding should be discontinued if the mother is treated with as part of this study (in either arm)
-
No active tumor bleeding: or radiographic evidence of major blood vessel infiltration as judged by the treating investigator
-
Prior -anti-cancer therapy is allowed: Patients need to be recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1), with the exception of alopecia. Any life-threatening events clearly attributable to prior immunotherapy exposure that have a high possibility of recurring should warrant exclusion: including severe pneumonitis, grade 4 bullous dermatitis/drug reaction with eosinophilia and systemic symptoms (DRESS), neurologic events such as autoimmune encephalitis transverse myelitis, and/or myocarditis. Maintenance hormonal replacement or long-term hormonal therapy exposure is permitted.
-
No chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to registration. Palliative (limited-field) radiation therapy is permitted, if all of the following criteria are met:
- Repeat imaging demonstrates no new sites of bone metastases.
- The lesion being considered for palliative radiation is not a target lesion
-
-
No patients with a prior malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen
-
Brain metastases allowed: Patients with treated brain metastases are eligible if follow-up brain imaging 3 weeks after central nervous system (CNS)-directed therapy shows no evidence of progression. Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration are eligible for this trial
-
For patients with evidence of chronic hepatitis B (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently receiving treatment, they are eligible if they have an undetectable HCV viral load
-
Solid organ or tissue transplant is allowed: - subsequent therapy with nivolumab increases the risk of organ/tissue rejection. Patients must be instructed that it is crucial they stay in touch with their transplant team during treatment
-
No active autoimmune disease: or history of autoimmune disease that might recur, and which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids. These include but are not limited to patients with a history of
- Immune related neurologic disease,
- Multiple sclerosis,
- Autoimmune (demyelinating) neuropathy,
- Guillain-Barre syndrome (GBS),
- Myasthenia gravis;
- Systemic autoimmune disease such as SLE,
- Connective tissue diseases,
- Scleroderma, inflammatory bowel disease (IBD),
- Crohn's, ulcerative colitis,
- Patients with a history of toxic epidermal necrolysis (TEN),
- Stevens-Johnson syndrome, or phospholipid syndrome should be excluded because of the risk of recurrence or exacerbation of disease
-
Patients with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible
-
Patients with rheumatoid arthritis and other arthropathies, Sjogren's syndrome, and psoriasis controlled with topical medication and patients with only positive serology, such as antinuclear antibodies (ANA) or anti-thyroid antibodies, should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible
-
Pneumonitis should be evaluated for the nature of the disease process, need for treatment prior study treatment, and the risk of exacerbation with study treatment
-
Able to swallow oral medication: No known medical condition causing an inability to swallow oral formulations of agents
-
No condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of study registration. Patients are permitted the use of topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). Adrenal replacement steroid doses > 10 mg daily prednisone are permitted. A brief (less than 3 weeks) course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by a contact allergen) is permitted
-
Concomitant anticoagulation with coumarin agents (e.g., warfarin), direct thrombin inhibitors (e.g., dabigatran), direct factor Xa inhibitor betrixaban, or platelet inhibitors (e.g., clopidogrel) is prohibited. Allowed anticoagulants are the following:
- Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines) and low-dose low molecular weight heparins (LMWH).
- Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban in subjects without known brain metastases who are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor
-
Concomitant use of any medications or substances that are strong inhibitors or inducers of CYP3A4 is discouraged; if unavoidable, the dose of cabozantinib on study should be adjusted accordingly. Any complementary medications (e.g., herbal supplements or traditional Chinese medicines) intended to treat the disease under study are prohibited
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Arm A (nivolumab, ipilimumab)
Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI and collection of blood samples throughout the trial. |
Given IV
Andre navne:
Undergo MRI
Andre navne:
Given IV
Andre navne:
Undergo collection of blood samples
Andre navne:
Undergo CT scan
Andre navne:
|
|
Eksperimentel: Arm B (nivolumab, ipilimumab, cabozantinib)
Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1 and cabozantinib S-malate PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients may continue with cabozantinib S-malate after 2 years per treating investigator. Patients undergo CT or MRI and collection of blood samples throughout the trial. |
Given IV
Andre navne:
Undergo MRI
Andre navne:
Given PO
Andre navne:
Given IV
Andre navne:
Undergo collection of blood samples
Andre navne:
Undergo CT scan
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression-free survival (PFS)
Tidsramme: From randomization to the first of either progression or death from any cause, or censored at last known tumor assessment date, assessed up to 2 years
|
PFS will be estimated using the Kaplan-Meier method, where the log-rank test will be used to compare the 2 treatment arms. |
From randomization to the first of either progression or death from any cause, or censored at last known tumor assessment date, assessed up to 2 years
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall survival (OS)
Tidsramme: From randomization to death from any cause, or censored at last known follow-up, assessed up to 2 years
|
OS will be estimated using the Kaplan-Meier method, where the log-rank test will be used to compare the 2 treatment arms. |
From randomization to death from any cause, or censored at last known follow-up, assessed up to 2 years
|
|
Incidence of adverse events
Tidsramme: Up to 2 years
|
The maximum grade for each type of adverse event will be summarized using Common Terminology Criteria for Adverse Events version 5.0. The frequency and percentage of grade 3+ adverse events will be compared between the 2 treatment arms. Comparisons between arms will be made by using either the chi-square or Fisher's exact test. |
Up to 2 years
|
|
Response by subgroups of interest
Tidsramme: Up to 2 years
|
Will also report and compare the overall response rate (ORR) between different subgroups of interest (primary or acquired PD-1/L1 inhibitor resistance in the prior line of therapy (further defined below), etc.). These comparisons will be done via chi-square or Fisher's exact tests. We'll also assess primary versus acquired resistance to prior PD-1 inhibition in each arm as well. While not a formal stratification, in the interim and final analysis we'll also descriptively assess these subgroups between arms as well. |
Up to 2 years
|
|
ORR
Tidsramme: Up to 2 years
|
The response rate will be compared via chi-square or Fisher's exact tests between the 2 treatment arms using both the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria and also separately for the immune-modified RECIST criteria. |
Up to 2 years
|
|
Predictors of response
Tidsramme: Up to 2 years
|
Will correlate the baseline data (Epstein-Barr virus viral load, p16 immunohistochemistry status, smoking history, and PD-L1 score) with ORR data. For this analysis, logistic regression models will be assessed using the baseline data to predict binary response data. Odds ratios and 95% confidence intervals will be reported. Will also summarize the data using descriptive statistics and graphical methods. |
Up to 2 years
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Ari J Rosenberg, Alliance for Clinical Trials in Oncology
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Stomatognatiske sygdomme
- Neoplasmer efter sted
- Neoplasmer
- Neoplasmer efter histologisk type
- Neoplasmer i hoved og hals
- Neoplasmer, kirtel og epitel
- Karcinom
- Otorhinolaryngologiske sygdomme
- Pharyngeale neoplasmer
- Otorhinolaryngologiske neoplasmer
- Nasopharyngeale sygdomme
- Pharyngeale sygdomme
- Nasopharyngeale neoplasmer
- Nasopharyngealt karcinom
- Aminosyrer, peptider og proteiner
- Proteiner
- Undersøgelsesteknikker
- Kliniske laboratorieteknikker
- Diagnostiske teknikker og procedurer
- Diagnose
- Biologiske faktorer
- Antistoffer, monoklonal, humaniseret
- Antistoffer, monoklonal
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serum globuliner
- Globuliner
- Kemiteknikker, analytisk
- Spektrumanalyse
- Receptorer, celleoverflade
- Membranproteiner
- Antigener
- Antigener, overflade
- Biomarkører
- Receptorer, immunologisk
- Antigener, differentiering, T-lymfocyt
- Antigener, differentiering
- Immune kontrolpunktsproteiner
- Costimulerende og inhiberende T-celle-receptorer
- Nivolumab
- Ipilimumab
- Håndtering af eksemplar
- Magnetisk resonansspektroskopi
- Cabozantinib
- CTLA-4-antigen
Andre undersøgelses-id-numre
- NCI-2023-04469
- U10CA180821 (U.S. NIH-bevilling/kontrakt)
- NCI-2023-04469 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- A092105 (Anden identifikator: CTEP)
- A092105 (Anden identifikator: Alliance for Clinical Trials in Oncology)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .